0001387131-22-002105.txt : 20220217
0001387131-22-002105.hdr.sgml : 20220217
20220217171716
ACCESSION NUMBER: 0001387131-22-002105
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220215
FILED AS OF DATE: 20220217
DATE AS OF CHANGE: 20220217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEDERMAN SETH
CENTRAL INDEX KEY: 0001563420
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36019
FILM NUMBER: 22649389
MAIL ADDRESS:
STREET 1: C/O TONIX PHARMACEUTICALS HOLDING CORP
STREET 2: 509 MADISON AVE., SUITE 306
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp.
CENTRAL INDEX KEY: 0001430306
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261434750
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 MAIN STREET, SUITE 101
CITY: CHATHAM
STATE: NJ
ZIP: 07928
BUSINESS PHONE: 212-980-9155
MAIL ADDRESS:
STREET 1: 26 MAIN STREET, SUITE 101
CITY: CHATHAM
STATE: NJ
ZIP: 07928
FORMER COMPANY:
FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC.
DATE OF NAME CHANGE: 20080320
4
1
lederman-form4_021522.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
X0306
4
2022-02-15
0
0001430306
Tonix Pharmaceuticals Holding Corp.
TNXP
0001563420
LEDERMAN SETH
C/O TONIX PHARMACEUTICALS HOLDING CORP
26 MAIN STREET, SUITE 101
CHATHAM
NJ
07928
1
1
0
0
Chief Executive Officer
Stock Option
0.207
2022-02-15
4
A
0
5000000
0.00
A
2023-02-15
2032-02-15
Common Stock
5000000
5000000
D
Stock Option
0.414
2022-02-15
4
A
0
5000000
0.00
A
2023-02-15
2032-02-15
Common Stock
5000000
5000000
D
Stock Option
0.621
2022-02-15
4
A
0
5000000
0.00
A
2023-02-15
2032-02-15
Common Stock
5000000
5000000
D
Stock Option
0.828
2022-02-15
4
A
0
5000000
0.00
A
2023-02-15
2032-02-15
Common Stock
5000000
5000000
D
One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance.
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.
/s/ Seth Lederman
2022-02-17